Juniper Biosciences

Juniper Biosciences is a precision oncology company based in Waltham, Massachusetts, focused on the development of targeted small molecule therapies. The company specializes in identifying and inhibiting specific kinase drivers that facilitate tumor growth and treatment resistance, particularly within the MAPK signaling pathway. Its lead development candidate, JB-101, is designed as a highly selective inhibitor for patients with genetically defined solid tumors. By integrating advanced medicinal chemistry with deep biological insights, Juniper Biosciences aims to deliver next-generation treatments for cancers with high unmet medical needs. The firm operates as a private entity, leveraging strategic expertise to advance its pipeline toward clinical validation.